The stock should find initial support at its 200-day moving average ... SmarTrend is tracking the current trend status for Pfizer Inc and will alert subscribers who have PFE in their portfolio or watchlist when shares have changed trend direction.
The last week has been an eventful one for pharma stocks with Novartis NVS announcing that it is acquiring gene therapy company AveXis while Merck MRK and AbbVie ABBV announced successful study results. In other news, Pfizer’s …
Everyone is so concerned with the likes of Pfizer (PFE), Johnson&Johnson (JNJ), Novartis (NVS ... He took a large stake in Celator (CPXX) which had a focus on …
And despite issuing better-than-predicted 2018 guidance, PFE stock fell as much as 2 percent in early morning trading. Heading into the earnings report, Pfizer shares were up 24 percent, matching the gains of the Standard & Poor's 500 …
It was a happening week for pharma stocks, Key developments this week included a new CAR-T deal for Pfizer PFE, successful study results from Pfizer, Lilly LLY and Allergan AGN and positive regulatory updates from AstraZeneca …
It is no secret that investors love stock buyback and dividend announcements. Within reason, companies raising dividends and increasing buybacks are particularly loved. Pfizer Inc. (NYSE: PFE) wants its part of the dividend hike and stock …
This high level of volatility gives investors the opportunity to enter into the stock, and potentially buy at an artificially low price. A question to answer is whether PFE’s current trading price of $35.38 reflective of the actual value of the large-cap?
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) reported fourth-quarter earnings Tuesday morning, marginally exceeding earnings expectations and meeting expected revenue numbers. And despite issuing better-than-predicted 2018 …
Pfizer Inc. (NYSE:PFE) isn’t the sexiest stock in the market, but that doesn’t mean investors shouldn’t be interested. PFE stock is up more than 2% in 2017, but down nearly 10% over the past year. Now may be as good a time as any to …